5 completed, 4 recruiting, 2 approved for marketing, 1 enrolling by invitation. 4 Phase 2, 3 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Completed 1 |
| Phase 3 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Graft-versus-Host Disease (GVHD): new trials by email Literature Review of Graft-versus-Host Disease (GVHD) trials Research Report on Graft-versus-Host Disease (GVHD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention Cyclophosphamide (primary intervention for GVHD prophylaxis) - Graft-versus-Host Disease (GVHD), Hematologic Malignancies | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 41 | 2026-03-09 | 2026-04-03 |
| Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus - Hematological Malignancies, Graft-versus-Host Disease (GVHD) | Phase 2 | Recruiting | University of Nebraska | 126 | 2025-06-23 | 2026-10-09 |
| Dapagliflozin in Allo-HCT for aGVHD Dapagliflozin (DAPA) - Graft-versus-host Disease (GVHD) | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 72 | 2025-04-26 | 2025-06-05 |
| A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux) - Graft-versus-host Disease (GVHD) | Phase 3 | Recruiting | Incyte Corporation | 572 | 2025-04-02 | 2026-10-22 |
| The Application of Novel Identified CD8 Regulatory Precursors in Inducing Immune Tolerance After Allo-HSCT Graft-versus-host Disease (GVHD) | Enrolling by invitation | Peking University People's Hospital | 100 | 2025-01-09 | 2025-03-07 | |
| GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease Itacitinib, Placebo, Prednisone - Graft-versus-host Disease (GVHD) | Phase 3 | Completed | Incyte Corporation | 439 | 2017-07-19 | 2025-09-02 |
| A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX) - Graft-versus-host Disease (GVHD) | Phase 3 | Completed | Incyte Corporation | 330 | 2017-06-29 | 2025-08-12 |
| A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) Ruxolitinib, Prednisone or methylprednisolone - Graft-versus-host Disease (GVHD) | Phase 2 | Completed | Incyte Corporation | 71 | 2016-12-30 | 2021-11-24 |
| Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids) - Graft-versus-host Disease (GVHD) | Phase 1 | Completed | Incyte Corporation | 31 | 2015-12-01 | 2019-03-08 |
| Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Basiliximab,, Tacrolimus, Methotrexate - Beta-Thalassemia Major, Graft-versus-host Disease (GVHD) | Phase 4 | Completed | Zhongming Zhang | 205 | 2015-04-01 | 2025-06-18 |
| Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD Ruxolitinib - Graft-versus-host Disease (GVHD) | Approved for marketing | Incyte Corporation | 2023-02-10 | |||
| An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant Ruxolitinib - Graft-versus-host Disease (GVHD) | Approved for marketing | Incyte Corporation | 2022-06-07 |
Graft vs Host Disease (12) · Bronchiolitis Obliterans Syndrome (2) · Hematologic Neoplasms (2) · beta-Thalassemia (1)
Immune System Diseases (12) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Bronchial Diseases (2) · Bronchiolitis (2) · Bronchiolitis Obliterans (2) · Bronchitis (2) · Lung Diseases (2) · Lung Diseases, Obstructive (2) · Neoplasms (2) · Neoplasms by Site (2) · Organizing Pneumonia (2) · Respiratory Tract Diseases (2) · Anemia (1) · Anemia, Hemolytic (1)
Mycophenolic Acid (5) · ruxolitinib (5) · Cyclophosphamide (3) · Methotrexate (3) · Methylprednisolone (3) · Prednisone (3) · Tacrolimus (3) · INCB039110 (2) · Sirolimus (2) · itacitinib (2) · Adrenal Cortex Hormones (1) · Basiliximab (1) · Everolimus (1) · Imatinib Mesylate (1) · Infliximab (1)
Incyte Corporation (7) · Milton S. Hershey Medical Center (1) · Peking University People's Hospital (1) · The First Affiliated Hospital of Soochow University (1) · University of Nebraska (1) · Zhongming Zhang (1)
United States (8) · China (3) · Australia (2) · Austria (2) · Belgium (2) · Czechia (2) · France (2) · Germany (2) · Greece (2) · Israel (2) · Italy (2) · Poland (2) · Portugal (2) · South Korea (2) · Spain (2)
Rodica Morariu-Zamfir, MD (2) · Fitzroy Dawkins, MD (1) · John Galvin, MD (1) · Joseph Cioccio, MD (1) · Moataz Ellithi, MBChB (1) · Pooja Khandelwal, MD (1) · Rodica Morariu-Zamfir (1)
PMID 29316837, PMID 35689489, PMID 16273116, PMID 16737942, PMID 32160294, PMID 32324888, PMID 34260836, PMID 34971577, PMID 35363318, PMID 36574342, PMID 40472328, PMID 40561385, PMID 42180389
2016 (1), 2017 (1)